Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

NIH Grants & Funding for B-Cell Acute Lymphoblastic Leukemia | Kisho | Kisho

Back to B-Cell Acute Lymphoblastic Leukemia

B-Cell Acute Lymphoblastic Leukemia — NIH Grants & Funding

Active and recent NIH-funded research on B-Cell Acute Lymphoblastic Leukemia. Data from NIH RePORTER, last 36 months.

MONDO:0004947

NIH-funded research on B-Cell Acute Lymphoblastic Leukemia

active grants

institutions

researchers

new in last 12 mo.

$45.4M in NIH funding over the last 36 months. Data from NIH RePORTER.

I'm looking for:

Or filter by research focus

Only show active grants

Basic Science(17)

Basic ScienceR01Active

A novel strategy for transcriptional reprogramming of lymphoid leukemia cells

CALABRETTA, BRUNO et al.·THOMAS JEFFERSON UNIVERSITY·PHILADELPHIA, PA

$540,022 (FY2022)

B-Cell Acute Lymphoblastic Leukemia — NIH Grants & Funding

Basic Science(17)

A novel strategy for transcriptional reprogramming of lymphoid leukemia cells

The Role and Function of a Novel Signature Gene in BCR::ABL1 (Ph) B-cell Acute Lymphoblastic Leukemia

Repeat enhancers as drivers of ETV6-RUNX1+ and ETV6-RUNX1-like B-lymphoblastic leukemia

Investigating and targeting NSD2 mutation-driven leukemia transformation

Central tolerance mechanisms in B-cell malignancies

Pathogenesis of ETV6-Related Acute Lymphoblastic Leukemia

Oncoprotein-regulated lineage plasticity in acute leukemia

Understanding the niche of minimal residual disease leukemia cells

Pre-BCR and STAT5 Signaling in Acute Lymphoblastic Leukemia

Eliminating B Cell Precursor Acute Lymphoblastic Leukemia by Targeting the Uniquely Specific Pre-B Cell Receptor

Translational(14)

Targeting CDK6 expression/activity in Ph+ and Ph1-like acute lymphoblastic leukemia (ALL)

Novel targeted therapy to reduce health disparities in pediatric leukemia

Targeted Inhibition in Leukemia

Dissecting the Functional Role of PAX5 Mutations in B-cell Acute Lymphoblastic Leukemia

Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies

Elucidating Critical Dependencies Underlying Therapeutic Evasion in Philadelphia Chromosome-like Acute Lymphoblastic Leukemia

Developing a novel therapeutic strategy for overcoming TKI resistance in ALL

Functional and Translational Epigenomics of Acute Lymphoblastic Leukemia

Understanding Ikaros molecular functions for targeted therapies of pre-B ALL

Novel use of PI3K inhibition to prevent recurrence of B-cell acute lymphoblastic leukemia

Clinical(3)

Predicting Relapse at the Time of Diagnosis in Acute Lymphoblastic Leukemia

Calming the Cytokine Storm: Unraveling the Biology of CRS and ICANS

Mechanisms of treatment failure in chimeric antigen receptor T cell therapy

Epi / Nat. History(3)

Defining the Mechanism of Genome Rearrangements in Ph-Like ALL to Determine Predictive Markers in High-Risk Hispanic Populations

Admixture analysis of acute lymphoblastic leukemia in African American children: the ADMIRAL Study

Sex and racial/ethnic differences in B-ALL genomics

Gene/Cell Therapy(8)

Off-the-Shelf Immune Effector Cells for Hematological Malignancies

Development of Novel Approaches to Optimize CAR T-cell Therapies for B-cell Malignancies

BAFF-R CAR T cell therapy for ALL

Inhibiting Free Fatty Acid Transport to Improve CAR-T Cell Therapy of Relapsed B-cell Acute Lymphoblastic Leukemia

Improving CAR T-cell therapy for Pediatric B-cell Acute Lymphoblastic Leukemia (B-ALL)

Optimizing outcomes for children and young adults with relapse of B-cell acute lymphoblastic leukemia after CD19-targeted chimeric antigen receptor T-cell therapy

Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL

Cassette exons in neoplastic pro-B-cells: implications for immunotherapy

Biomarker / Dx(1)

Brain-Imaging Markers of Neurotoxicity and Long-Term Outcomes after CAR-T Cell Therapy